Phoenix Biosciences, Inc. Issued United States Patent for the Clinical Development of PBS119 For HIV/AIDS; New patent marks first step towards clinical studies.
HOLLYWOOD, Fla. -- Phoenix Biosciences, Inc. (PBS PBS
in full Public Broadcasting Service
Private, nonprofit U.S. corporation of public television stations. PBS provides its member stations, which are supported by public funds and private contributions rather than by commercials, with educational, cultural, ), focused on developing affordable, non-toxic treatments for HIV/AIDS HIV/AIDS Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome , announced today that the U.S. Patent and trademark office has granted PBS Patent Number 6,734,192. This patent was provided to Phoenix Biosciences, Inc., for their novel immunological method, which claims to reduce HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. activity.
"The approval of this patent is an important step for our development team to move forward with clinical studies of PBS119," said Dr. Robert Keller, Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Phoenix Biosciences. "Phoenix Biosciences will now aggressively pursue the execution of Phase I/II clinical trials, which will focus on patients experiencing drug resistance."
PBS119 utilizes a novel clinical approach being investigated for safety and clinical efficacy for advanced stage HIV/AIDS disease. PBS119 has been identified as having immune rebuilding potential and antiviral antiviral /an·ti·vi·ral/ (-vi´ral) destroying viruses or suppressing their replication, or an agent that so acts.
adj. activity. Phoenix Biosciences is currently pursuing initial human studies that will be conducted in compliance with federal clinical trial guidelines.
Dr. Keller has been in clinical practice for the treatment of HIV/AIDS for 25 years and is certified and also sits on the Board of Governors for the Florida Chapter of the American Academy The American Academy in Berlin is a non-partisan academic institution in Berlin. It was founded in September 1994 by a group of prominent Americans and Germans, among them Richard Holbrooke, Henry Kissinger, Richard von Weizsäcker, Fritz Stern and Otto Graf Lambsdorff and opened in of HIV medicine. In addition, the Consumers' Research Council of America has voted Keller as one of America's top physicians in the field of immunology.
About Phoenix Biosciences, Inc.
Phoenix Biosciences, Inc., an emerging biotech company focused on developing affordable, non-toxic treatments for HIV/AIDS, Hepatitis and viral infections. The company's current lead research compound PBS119 indicates to possess broad spectrum HIV specific qualities. With headquarters in Hollywood, Florida Hollywood is a city in Broward County, Florida, United States. As of 1 July 2006, the population estimated by the U.S. Census Bureau is 145,879. Founded in 1925, the city grew rapidly in the 1950s and 1960s, and is now the ninth largest city in Florida. , Phoenix Biosciences, Inc. is a privately-held biotech company. For more information about Phoenix Biosciences, Inc., please email email@example.com or visit www.robkellermd.org.